Intensity Therapeutics, Inc. (INTS)
3.35
-0.03
(-0.89%)
USD |
NASDAQ |
Oct 16, 16:00
3.27
-0.08
(-2.39%)
After-Hours: 20:00
Intensity Therapeutics Enterprise Value : 0.4338M for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | 0.4338M |
| October 15, 2026 | 0.5221M |
| October 14, 2026 | 0.64M |
| October 13, 2026 | 1.023M |
| October 12, 2026 | 0.3159M |
| October 09, 2026 | 1.258M |
| October 08, 2026 | 1.406M |
| October 07, 2026 | 1.759M |
| October 06, 2026 | 1.023M |
| October 05, 2026 | 0.7283M |
| October 02, 2026 | 0.6989M |
| October 01, 2026 | 0.0214M |
| September 30, 2026 | 0.4927M |
| September 29, 2026 | 0.64M |
| September 28, 2026 | 1.317M |
| September 25, 2026 | 1.759M |
| September 24, 2026 | 2.024M |
| September 23, 2026 | 2.643M |
| September 22, 2026 | 2.378M |
| September 21, 2026 | 2.407M |
| September 18, 2026 | 2.672M |
| September 17, 2026 | 1.995M |
| September 16, 2026 | 1.789M |
| September 15, 2026 | 1.789M |
| September 14, 2026 | 2.290M |
| Date | Value |
|---|---|
| September 11, 2026 | 2.407M |
| September 10, 2026 | 2.466M |
| September 09, 2026 | 2.407M |
| September 08, 2026 | 2.614M |
| September 04, 2026 | 2.643M |
| September 03, 2026 | 2.348M |
| September 02, 2026 | 2.348M |
| September 01, 2026 | 2.555M |
| August 31, 2026 | 2.967M |
| August 28, 2026 | 3.085M |
| August 27, 2026 | 3.144M |
| August 26, 2026 | 3.910M |
| August 25, 2026 | 4.985M |
| August 24, 2026 | 4.558M |
| August 21, 2026 | 4.882M |
| August 20, 2026 | 4.940M |
| August 19, 2026 | 2.938M |
| August 18, 2026 | 2.967M |
| August 17, 2026 | 2.790M |
| August 14, 2026 | 2.231M |
| August 13, 2026 | 2.348M |
| August 12, 2026 | 2.820M |
| August 11, 2026 | 2.938M |
| August 10, 2026 | 3.203M |
| August 07, 2026 | 2.820M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.664B |
| Oncolytics Biotech, Inc. | 58.41M |
| Sangamo Therapeutics, Inc. | 37.40M |
| Sarepta Therapeutics, Inc. | 2.064B |
| Anixa Biosciences, Inc. | 77.38M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.007M |
| Total Expenses (Quarterly) | 3.007M |
| EPS Diluted (Quarterly) | -1.111 |
| Earnings Yield | -144.2% |
| Normalized Earnings Yield | -144.22 |